These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 27717544)

  • 21. Dual Targeting Strategies on Histone Deacetylase 6 (HDAC6) and Heat Shock Protein 90 (Hsp90).
    Bonanni D; Citarella A; Moi D; Pinzi L; Bergamini E; Rastelli G
    Curr Med Chem; 2022; 29(9):1474-1502. PubMed ID: 34477503
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
    Martin SK; Kyprianou N
    Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular biology of castration-resistant prostate cancer: basis for the novel therapeutic targets.
    Mellado B; Marin Aguilera M; Pereira MV
    Arch Esp Urol; 2013 Jun; 66(5):453-62. PubMed ID: 23793763
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Simultaneous targeting of androgen receptor (AR) and MAPK-interacting kinases (MNKs) by novel retinamides inhibits growth of human prostate cancer cell lines.
    Ramamurthy VP; Ramalingam S; Gediya L; Kwegyir-Afful AK; Njar VC
    Oncotarget; 2015 Feb; 6(5):3195-210. PubMed ID: 25605250
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design and synthesis of orally bioavailable aminopyrrolidinone histone deacetylase 6 inhibitors.
    Lin X; Chen W; Qiu Z; Guo L; Zhu W; Li W; Wang Z; Zhang W; Zhang Z; Rong Y; Zhang M; Yu L; Zhong S; Zhao R; Wu X; Wong JC; Tang G
    J Med Chem; 2015 Mar; 58(6):2809-20. PubMed ID: 25734520
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of histone deacetylase and DNA methyltransferase inhibitors on the expression of the androgen receptor gene in androgen-independent prostate cancer cell lines.
    Fialova B; Smesny Trtkova K; Paskova L; Langova K; Kolar Z
    Oncol Rep; 2013 May; 29(5):2039-45. PubMed ID: 23503510
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Androgen receptor: role and novel therapeutic prospects in prostate cancer.
    Taplin ME
    Expert Rev Anticancer Ther; 2008 Sep; 8(9):1495-508. PubMed ID: 18759700
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor.
    Kovacs JJ; Murphy PJ; Gaillard S; Zhao X; Wu JT; Nicchitta CV; Yoshida M; Toft DO; Pratt WB; Yao TP
    Mol Cell; 2005 May; 18(5):601-7. PubMed ID: 15916966
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
    Shafi AA; Yen AE; Weigel NL
    Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Emodin down-regulates androgen receptor and inhibits prostate cancer cell growth.
    Cha TL; Qiu L; Chen CT; Wen Y; Hung MC
    Cancer Res; 2005 Mar; 65(6):2287-95. PubMed ID: 15781642
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Hsp90 inhibitor, 17-AAG, prevents the ligand-independent nuclear localization of androgen receptor in refractory prostate cancer cells.
    Saporita AJ; Ai J; Wang Z
    Prostate; 2007 Apr; 67(5):509-20. PubMed ID: 17221841
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Formation of AR-SMRT binding in prostate cancer cells treated with natural histone deacetylase inhibitor.
    Trtková K; Pašková L; Matiješčuková N; Kolář Z
    Cancer Biomark; 2010; 7(2):79-90. PubMed ID: 21178266
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design, synthesis, and biological evalution of bifunctional inhibitors against Hsp90-HDAC6 interplay.
    Chae HY; Park SY; Jha S; Gupta SK; Kim M; Ha E; Seo YH
    Eur J Med Chem; 2022 Oct; 240():114582. PubMed ID: 35834905
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
    Yu CC; Pan SL; Chao SW; Liu SP; Hsu JL; Yang YC; Li TK; Huang WJ; Guh JH
    Biochem Pharmacol; 2014 Aug; 90(3):320-30. PubMed ID: 24915421
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies.
    Moilanen AM; Riikonen R; Oksala R; Ravanti L; Aho E; Wohlfahrt G; Nykänen PS; Törmäkangas OP; Palvimo JJ; Kallio PJ
    Sci Rep; 2015 Jul; 5():12007. PubMed ID: 26137992
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer models.
    Gravina GL; Marampon F; Giusti I; Carosa E; Di Sante S; Ricevuto E; Dolo V; Tombolini V; Jannini EA; Festuccia C
    Int J Oncol; 2012 Mar; 40(3):711-20. PubMed ID: 22134754
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Crystal structures of AKR1C3 containing an N-(aryl)amino-benzoate inhibitor and a bifunctional AKR1C3 inhibitor and androgen receptor antagonist. Therapeutic leads for castrate resistant prostate cancer.
    Chen M; Adeniji AO; Twenter BM; Winkler JD; Christianson DW; Penning TM
    Bioorg Med Chem Lett; 2012 May; 22(10):3492-7. PubMed ID: 22507964
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rational design of synthetically tractable HDAC6/HSP90 dual inhibitors to destroy immune-suppressive tumor microenvironment.
    Wu TY; Chen M; Chen IC; Chen YJ; Chen CY; Wang CH; Cheng JJ; Nepali K; Chuang KH; Liou JP
    J Adv Res; 2023 Apr; 46():159-171. PubMed ID: 35752438
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Searching for Novel HDAC6/Hsp90 Dual Inhibitors with Anti-Prostate Cancer Activity: In Silico Screening and In Vitro Evaluation.
    Pinzi L; Belluti S; Piccinini I; Imbriano C; Rastelli G
    Pharmaceuticals (Basel); 2024 Aug; 17(8):. PubMed ID: 39204176
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synergistic Interaction of Histone Deacetylase 6- and MEK-Inhibitors in Castration-Resistant Prostate Cancer Cells.
    Corno C; Arrighetti N; Ciusani E; Corna E; Carenini N; Zaffaroni N; Gatti L; Perego P
    Front Cell Dev Biol; 2020; 8():610. PubMed ID: 32754596
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.